Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is a private, preclinical-stage biotech targeting the root cause of neurodegenerative diseases through a novel mechanism involving pathological biomolecular condensates. The company's platform, born from the seminal discovery of the stress granule-disease connection by its CSO, aims to develop oral small molecules that could halt disease progression in ALS and Alzheimer's. With a seasoned leadership team, validation from major pharma partnerships, and compelling preclinical data showing ~70% reduction in tau pathology, Aquinnah is positioning itself as a potential disruptor in a field with immense unmet need. Its progress is supported by peer-reviewed grants and strategic industry collaborations.

Small molecule platform targeting pathological biomolecular condensates (e.g., stress granules) driven by RNA-binding proteins to prevent toxic protein aggregation in neurodegenerative diseases.

Aquinnah competes in the crowded Alzheimer's and ALS spaces against large pharma (e.g., Biogen, Eisai, Roche) and numerous biotechs targeting amyloid, tau, neuroinflammation, and other pathways. Its key differentiation is the novel focus on preventing pathological biomolecular condensates, a upstream target with potential applicability across multiple proteinopathies, and the development of convenient oral small molecules.